Evidence map›Paper›PMID 31555644›Full record

ReviewFrontiers in cell and developmental biology2019

Breast Tissue Biology Expands the Possibilities for Prevention of Age-Related Breast Cancers.

Tara Fresques, Arrianna Zirbes, Sundus Shalabi, Susan Samson, Sandy Preto, Martha R Stampfer, Mark A LaBarge

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Splicing alterations in healthy aging and disease.Wiley interdisciplinary reviews. RNA · 2021
    Review
  3. The Effects of Lifetime Estrogen Exposure on Breast Epigenetic Age.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Tara FresquesDepartment of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA, United States.
Arrianna ZirbesDepartment of Population Sciences, Beckman Research Institute at City of Hope, Duarte, CA, United States.
Sundus ShalabiDepartment of Population Sciences, Beckman Research Institute at City of Hope, Duarte, CA, United States.
Susan SamsonBreast Science Advocacy Core, Breast Oncology Program, University of California, San Francisco, San Francisco, CA, United States.
Sandy PretoNotes4Hope, Moraga, CA, United States.
Martha R StampferDepartment of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA, United States.
Mark A LaBargeDepartment of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA, United States.
Lawrence Berkeley National Laboratory · USCity of Hope · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preventing breast cancer before it is able to form is an ideal way to stop breast cancer. However, there are limited existing options for prevention of breast cancer. Changes in the breast tissue resulting from the aging process contribute to breast cancer susceptibility and progression and may therefore provide promising targets for prevention. Here, we describe new potential targets, immortalization and inflammaging, that may be useful for prevention of age-related breast cancers. We also summarize existing studies of warfarin and metformin, current drugs used for non-cancerous diseases, that also may be repurposed for breast cancer prevention.

Indexed as

breast cancerchemopreventionimmortalityinflammagingmetforminpreventionwarfarin

Identifiers

PMID31555644
PMCPMC6722426
OpenAlexW2967708267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.